These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

203 related items for PubMed ID: 15360093

  • 1. Overview of newer antimicrobial formulations for overcoming pneumococcal resistance.
    Craig WA.
    Am J Med; 2004 Aug 02; 117 Suppl 3A():16S-22S. PubMed ID: 15360093
    [Abstract] [Full Text] [Related]

  • 2. Augmentin (amoxicillin/clavulanate) in the treatment of community-acquired respiratory tract infection: a review of the continuing development of an innovative antimicrobial agent.
    White AR, Kaye C, Poupard J, Pypstra R, Woodnutt G, Wynne B.
    J Antimicrob Chemother; 2004 Jan 02; 53 Suppl 1():i3-20. PubMed ID: 14726431
    [Abstract] [Full Text] [Related]

  • 3. Susceptibility patterns of Streptococcus pneumoniae isolates in North America (2002-2003): contemporary in vitro activities of amoxicillin/clavulanate and 15 other antimicrobial agents.
    Pottumarthy S, Fritsche TR, Sader HS, Stilwell MG, Jones RN.
    Int J Antimicrob Agents; 2005 Apr 02; 25(4):282-9. PubMed ID: 15784306
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Building in efficacy: developing solutions to combat drug-resistant S. pneumoniae.
    Jacobs MR.
    Clin Microbiol Infect; 2004 Apr 02; 10 Suppl 2():18-27. PubMed ID: 14759230
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Comparative in vitro activity of a pharmacokinetically enhanced oral formulation of amoxicillin/clavulanic acid (2000/125 mg twice daily) against 9172 respiratory isolates collected worldwide in 2000.
    Koeth LM, Jacobs MR, Good CE, Bajaksouzian S, Windau A, Jakielaszek C, Saunders KA.
    Int J Infect Dis; 2004 Nov 02; 8(6):362-73. PubMed ID: 15494258
    [Abstract] [Full Text] [Related]

  • 8. Efficacy of high-dose amoxicillin-clavulanate against experimental respiratory tract infections caused by strains of Streptococcus pneumoniae.
    Woodnutt G, Berry V.
    Antimicrob Agents Chemother; 1999 Jan 02; 43(1):35-40. PubMed ID: 9869562
    [Abstract] [Full Text] [Related]

  • 9. Two pharmacodynamic models for assessing the efficacy of amoxicillin-clavulanate against experimental respiratory tract infections caused by strains of Streptococcus pneumoniae.
    Woodnutt G, Berry V.
    Antimicrob Agents Chemother; 1999 Jan 02; 43(1):29-34. PubMed ID: 9869561
    [Abstract] [Full Text] [Related]

  • 10. Performance in practice: bacteriological efficacy in patients with drug-resistant S. pneumoniae.
    Garau J.
    Clin Microbiol Infect; 2004 Apr 02; 10 Suppl 2():28-35. PubMed ID: 14759231
    [Abstract] [Full Text] [Related]

  • 11. Spotlight on amoxicillin/clavulanic acid 2000 mg/125 mg extended release (XR) in respiratory tract infections in adults.
    McCormack PL, Keating GM.
    Treat Respir Med; 2005 Apr 02; 4(5):361-2. PubMed ID: 16137193
    [Abstract] [Full Text] [Related]

  • 12. Clarithromycin extended-release tablet: a review of its use in the management of respiratory tract infections.
    Darkes MJ, Perry CM.
    Am J Respir Med; 2003 Apr 02; 2(2):175-201. PubMed ID: 14720016
    [Abstract] [Full Text] [Related]

  • 13. Proof of concept: performance testing in models.
    Craig WA.
    Clin Microbiol Infect; 2004 Apr 02; 10 Suppl 2():12-7. PubMed ID: 14759229
    [Abstract] [Full Text] [Related]

  • 14. Achieving bacterial eradication using pharmacokinetic/pharmacodynamic principles.
    Dagan R.
    Int J Infect Dis; 2003 Mar 02; 7 Suppl 1():S21-6. PubMed ID: 12839704
    [Abstract] [Full Text] [Related]

  • 15. Microbiological and pharmacodynamic considerations in the treatment of infection due to antimicrobial-resistant Streptococcus pneumoniae.
    Appelbaum PC.
    Clin Infect Dis; 2000 Aug 02; 31 Suppl 2():S29-34. PubMed ID: 10984325
    [Abstract] [Full Text] [Related]

  • 16. Extended release amoxicillin/clavulanate: optimizing a product for respiratory infections based on pharmacodynamic principles.
    Jacobs MR.
    Expert Rev Anti Infect Ther; 2005 Jun 02; 3(3):353-60. PubMed ID: 15954852
    [Abstract] [Full Text] [Related]

  • 17. Therapeutic options for pneumococcal pneumonia in Turkey.
    Oncu S, Erdem H, Pahsa A.
    Clin Ther; 2005 Jun 02; 27(6):674-83. PubMed ID: 16117975
    [Abstract] [Full Text] [Related]

  • 18. E test for studying in vitro activity of seven antimicrobial agents against penicillin-susceptible and penicillin-resistant pneumococci.
    Li J, Zhang Y, Chen Y, Hao F, Chen Y.
    Chin Med J (Engl); 2000 Jul 02; 113(7):628-31. PubMed ID: 11776034
    [Abstract] [Full Text] [Related]

  • 19. [Pharmacodynamic basis for the use of amoxicillin-clavulanic acid in respiratory infections due to Streptococcus pneumoniae: In vitro studies in an experimental model].
    Gómez-Lus ML, García Y, Valero E, Amores R, Fuentes F.
    Rev Esp Quimioter; 2000 Sep 02; 13(3):306-13. PubMed ID: 11086282
    [Abstract] [Full Text] [Related]

  • 20. The efficacy of cefditoren pivoxil in the treatment of lower respiratory tract infections, with a focus on the per-pathogen bacteriologic response in infections caused by Streptococcus pneumoniae and Haemophilus influenzae: a pooled analysis of seven clinical trials.
    Granizo JJ, Giménez MJ, Barberán J, Coronel P, Gimeno M, Aguilar L.
    Clin Ther; 2006 Dec 02; 28(12):2061-9. PubMed ID: 17296462
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.